🎉 M&A multiples are live!
Check it out!

Public Comps and Valuation Multiples
for Regenerative Medicine

Benchmark revenue and EBITDA valuation multiples for public comps like Vertex Pharmaceuticals, BioMarin Pharmaceutical, VCANBIO, Mesoblast and Amicus Therapeutics.

Regenerative Medicine

See analyst estimates and all valuation multiples for Regenerative Medicine
Company EV EV/LTM Revenue EV/LTM EBITDA
$118B 10.3x 36.4x
$10.8B 3.6x 14.0x
$3.9B 12.3x 29.8x
$3.7B 10.6x 28.1x
$3.6B 90.7x -7.8x
$2.5B 692.7x -64.6x
$2.2B 3.8x 33.9x
$2.1B 7.9x 32.4x
$1.5B n/a n/a
$1.5B 67.9x -50.5x
$1.1B 18.8x -2.6x
$1.1B 1819.9x -43.9x
$940M 2.6x 12.1x
$872M 15.4x -1.9x
$624M 1.3x 12.3x
$582M 2.9x 26.3x
$560M 7.9x 28.4x
$471M 16.7x -2.9x
$470M n/a n/a
$431M 12.1x 24.5x
$378M 5.4x -22.4x
$347M 85.4x n/a
$313M 258.1x n/a
$288M n/a n/a
$237M 2456.2x -1.4x
$196M 24.5x -8.3x
$186M 0.6x n/a
$178M 29.1x -55.7x
$170M n/a n/a
$154M 5.4x 11.0x
$132M 1.1x 17.9x
$121M 2.2x 39.0x
$119M n/a n/a
$109M 4.1x -8.9x
$91.6M n/a n/a
$71.2M n/a -5.1x
$59.3M n/a n/a
$51.9M 192.3x -0.2x
$48.3M 35.1x n/a
$24.3M n/a n/a
$23.0M n/a n/a
$20.7M 5.2x n/a
$16.8M 21.8x -3.5x
$9.8M 1.7x n/a
$9.5M 4.6x n/a
-$161M -2.7x 0.8x

Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.

See analyst estimates and M&A multiples for Regenerative Medicine

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.